Author:
Sakaue Tomoko,Sugawara Tamie,Sugisita Yoshiyuki,Kurita Junko,Nohara Michiko,Ohkusa Yasushi
Abstract
AbstractBackground and objectiveIn Japan, routine administration of two-dose immunization for varicella to one-year-old children was introduced in October, 2014. The objective of this study was measurement of the effectiveness of routine two-dose immunization for varicella to onset and assessment of severity in a nursery school setting.MethodThe study period extended from the beginning of April, 2017 through March, 2018. The study area was Nursery school B in a city A. Subjects were 120 children in all. We analyzed vaccine efficacy (VE) as an observational study and assessed severity using Fisher’s exact test. We also assessed VE for severity using linear regression. Severity was defined as the length of school absence attributable to varicella infection.ResultsFor one dose or more, VE was 48.1% for all ages and 49.2% among children three years old and older. No significant VE was found. Vaccination using one dose or more can reduce severity significantly.Discussion and conclusionLow VE was found in a nursery school setting, although results were not significant. VE for severity was confirmed, but a second dose might not reduce severity.
Publisher
Cold Spring Harbor Laboratory
Reference18 articles.
1. The neurotropic herpes viruses: herpes simplex and varicella-zoster
2. Marin M , Marti M , Kambhampati A , Jeram SM , Seward JF . Global Varicella Vaccine Effectiveness: A Meta-analysis. Pediatrics 2016, 137
3. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model;PloS One,2019
4. Ministry of Health, Labour and Welfare, Japan. Guideline for Infection Control at Nursery Schools (revised version). 2018. https://www.mhlw.go.jp/file/06-Seisakujouhou11900000-Koyoukintoujidoukateikyoku/0000201596.pdf (in Japanese) [accessed on 5 February 2020]
5. Protection against varicella with two doses of combined measles–mumps–rubella–varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial;The Lancet,2014